Legend Biotech has emerged as one of the most successful cell therapy companies globally, with its BCMA-targeted CAR-T therapy CARVYKTI achieving approximately $1.9 billion in global end-user sales during 2025.

Core Business

Legend Biotech is a global biotechnology company focused exclusively on developing and commercializing novel cell therapies. Its sole commercial product, CARVYKTI (ciltacabtagene autoleucel), is a BCMA-directed CAR-T therapy for relapsed/refractory multiple myeloma that generated approximately $1.9 billion in global end-user sales during 2025. The company recorded $627 million in recognized revenue and has treated over 10,000 patients across 18 markets.

Global Presence

Headquartered in Somerset, New Jersey, with roots in Nanjing, China, Legend Biotech operates across 18 core markets. Its manufacturing network includes a major facility in Raritan, New Jersey (with annual capacity for 10,000 patients in partnership with Johnson & Johnson) and a planned European facility in Ghent, Belgium. The company employs approximately 1,500 people globally.

Key Strengths

Legend Biotech's extraordinary growth trajectory — CARVYKTI sales reaching $1.9 billion — demonstrates exceptional commercial execution. The company is one of the few pure-play CGT companies to achieve profitability, with $835 million in cash reserves funding continued expansion. Its exclusive focus on cell therapy, combined with the Johnson & Johnson partnership, provides both undiluted strategic attention and significant commercial resources for global market development.

VerityRank Score

Legend Biotech achieves a VerityRank Score of 85/100, reflecting its exceptional single-product commercial success, 100% pure-play CGT focus, and rapid global manufacturing scale-up capability.